GYNECOLOGIC CANCERS

Pembrolizumab (Keytruda) has been granted a priority review by the FDA for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

In an 8 to 4 vote, the FDA's Oncologic Drugs Advisory Committee recommended approval of blinatumomab for the treatment of minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.

Lung Cancer

The FDA has granted a fast track designation to pamrevlumab for the treatment of patients with locally advanced, unresectable pancreatic cancer, according to FibroGen, the manufacturer of the first-in-class anti-CTGF antibody.

Kathleen Moore, MD, associate director for clinical research at the Stephenson Oklahoma Cancer Center, discusses the development of combination therapy strategies for patients with ovarian cancer.

Clinical Approach for Platinum-Sensitive Recurrent Ovarian Cancer

Northwell Health Cancer Institute has appointed Richard R. Barakat, MD, to lead all cancer services and research. Barakat will serve as physician-in-chief and director of the Northwell Health Cancer Institute, senior vice president of the health system’s Cancer Service Line, and professor of Obstetrics and Gynecology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Rebecca C. Arend, MD, discusses novel combinations being investigated for the treatment of patients with ovarian cancer.

Kathleen Moore, MD,&nbsp;discusses combination strategies with immunotherapy for patients with ovarian cancer during the&nbsp;2018 Society of Gynecologic Oncology Annual Winter Meeting.<br /> &nbsp;

During the 2018 Society of Gynecologic Oncology Annual Winter Meeting, Camille Gunderson, MD,&nbsp;detailed some of the active trials currently exploring PARP inhibitors in combination with either anti-VEGF therapy or immunotherapy in ovarian cancer.

Women with newly diagnosed stage III&nbsp;epithelial ovarian cancer experienced an improvement in&nbsp;relapse-free survival and overall survival with the addition of&nbsp;hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery, according to results&nbsp;from a multicenter, open-label, phase III trial.

According to results of an open-label, single-center, 2-stage, proof-of-concept phase II study, prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, demonstrated clinical activity and was tolerable in&nbsp;women with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma.

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.&nbsp;

Hackensack Meridian Health has announced that Verda J. Hicks, MD, FACS, FACOG, will serve as its chief of Gynecologic Oncology at Jersey Shore University Medical Center. She will be joined by associates James R. Bosscher, MD, and Karim ElSahwi, MD, to facilitate promising experience and care to the Monmouth, Ocean, and Middlesex counties.

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charit&eacute; Center Gynecology, Charit&eacute; &ndash; Universitatsmedizin Berlin, discusses a randomized controlled phase II study to evaluate secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.